Long-range gene regulation and novel therapeutic applications

Blood

Volumn 125, Issue 10, 2015, Pages 1521-1525

  Van Den Heuvel, Anita ^a   Stadhouders, Ralph ^a,d   Andrieu Soler, Charlotte ^b   Grosveld, Frank ^a   Soler, Eric ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d CENTRE FOR GENOMIC REGULATION CRG   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ENHANCER REGION; GENE CONTROL; GENETIC DISORDER; GENETIC TRANSCRIPTION; GENOME; GENOME ANALYSIS; HUMAN; PRIORITY JOURNAL; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN GENOME; PROCEDURES; REGULATORY SEQUENCE; RNA EDITING;

ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENOME, HUMAN; HUMANS; REGULATORY ELEMENTS, TRANSCRIPTIONAL; RNA EDITING;

EID: 84928431514     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-11-567925     Document Type: Article

References (80)

1. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74.
2. Kellis M, Wold B, Snyder MP, et al. Defining functional DNA elements in the human genome. Proc Natl Acad Sci USA. 2014;111(17):6131-6138.
3. Stamatoyannopoulos JA. What does our genome encode? Genome Res. 2012;22(9):1602-1611.
4. Ong C-T, Corces VG. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat Rev Genet. 2011;12(4):283-293.
5. Bulger M, Groudine M. Functional and mechanistic diversity of distal transcription enhancers. Cell. 2011;144(3):327-339.
6. Farh KK-H, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2014 Oct 29. doi: 10.1038/nature13835.
7. Gröschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157(2):369-381.
8. Herranz D, Ambesi-Impiombato A, Palomero T, et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med. 2014;20(10):1130-1137.
9. Corcoran LM, Cory S, Adams JM. Transposition of the immunoglobulin heavy chain enhancer to the myc oncogene in a murine plasmacytoma. Cell. 1985;40(1):71-79.
10. Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z. Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci USA. 1996;93(12):6129-6134.
11. Fahrlander PD, Sümegi J, Yang JQ, Wiener F, Marcu KB, Klein G. Activation of the c-myc oncogene by the immunoglobulin heavy-chain gene enhancer after multiple switch region-mediated chromosome rearrangements in a murine plasmacytoma. Proc Natl Acad Sci USA. 1985;82(11):3746-3750.
12. Lettice LA, Heaney SJ, Purdie LA, et al. A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. Hum Mol Genet. 2003;12(14):1725-1735.
13. Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013;342(6155):253-257.
14. Stadhouders R, Aktuna S, Thongjuea S, et al. HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers. J Clin Invest. 2014;124(4):1699-1710.
15. Visser M, Kayser M, Palstra R-J. HERC2 rs12913832 modulates human pigmentation by attenuating chromatin-loop formation between a long-range enhancer and the OCA2 promoter. Genome Res. 2012;22(3):446-455.
16. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA. 2009;106(23):9362-9367.
17. Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet. 2014;46(11):1160-1165.
18. Kioussis D, Vanin E, deLange T, Flavell RA, Grosveld FG. Beta-globin gene inactivation by DNA translocation in gamma beta-thalassaemia. Nature. 1983;306(5944):662-666.
19. Soudon J, Bernard O, Mathieu-Mahul D, Larsen CJ. c-myc gene expression in a leukemic T-cell line bearing a t(8;14) (q24;q11) translocation. Leukemia. 1991;5(1):60-65.
20. Andersson R, Gebhard C, Miguel-Escalada I, et al; FANTOM Consortium. An atlas of active enhancers across human cell types and tissues. Nature. 2014;507(7493):455-461.
21. Heintzman ND, Hon GC, Hawkins RD, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 2009;459(7243):108-112.
22. Ho JWK, Jung YL, Liu T, et al. Comparative analysis of metazoan chromatin organization. Nature. 2014;512(7515):449-452.
23. Sanyal A, Lajoie BR, Jain G, Dekker J. The longrange interaction landscape of gene promoters. Nature. 2012;489(7414):109-113.
24. Velagaleti GVN, Bien-Willner GA, Northup JK, et al. Position effects due to chromosome breakpoints that map approximately 900 Kb upstream and approximately 1.3 Mb downstream of SOX9 in two patients with campomelic dysplasia. Am J Hum Genet. 2005;76(4):652-662.
25. Smemo S, Tena JJ, Kim K-H, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature. 2014;507(7492):371-375.
26. Tolhuis B, Palstra RJ, Splinter E, Grosveld F, de Laat W. Looping and interaction between hypersensitive sites in the active beta-globin locus. Mol Cell. 2002;10(6):1453-1465.
27. Hughes JR, Lower KM, Dunham I, et al. High-resolution analysis of cis-acting regulatory networks at the α-globin locus. Philos Trans R Soc Lond B Biol Sci. 2013;368(1620):20120361.
28. Vernimmen D. Uncovering enhancer functions using the α-globin locus. PLoS Genet. 2014;10(10):e1004668.
29. Stadhouders R, Thongjuea S, Andrieu-Soler C, et al. Dynamic long-range chromatin interactions control Myb proto-oncogene transcription during erythroid development. EMBO J. 2012;31(4):986-999.
30. Jing H, Vakoc CR, Ying L, et al. Exchange of GATA factors mediates transitions in looped chromatin organization at a developmentally regulated gene locus. Mol Cell. 2008;29(2):232-242.
31. Ghavi-Helm Y, Klein FA, Pakozdi T, et al. Enhancer loops appear stable during development and are associated with paused polymerase. Nature. 2014;512(7512):96-100.
32. Maksimenko O, Georgiev P. Mechanisms and proteins involved in long-distance interactions. Front Genet. 2014;5:28.
33. Gorkin DU, Leung D, Ren B. The 3D genome in transcriptional regulation and pluripotency. Cell Stem Cell. 2014;14(6):762-775.
34. van Arensbergen J, van Steensel B, Bussemaker HJ. In search of the determinants of enhancer-promoter interaction specificity. Trends Cell Biol. 2014;24(11):695-702.
35. Drissen R, Palstra R-J, Gillemans N, et al. The active spatial organization of the beta-globin locus requires the transcription factor EKLF. Genes Dev. 2004;18(20):2485-2490.
36. Song S-H, Hou C, Dean A. A positive role for NLI/Ldb1 in long-range beta-globin locus control region function. Mol Cell. 2007;28(5):810-822.
37. Krivega I, Dale RK, Dean A. Role of LDB1 in the transition from chromatin looping to transcription activation. Genes Dev. 2014;28(12):1278-1290.
38. Stadhouders R, de Bruijn MJW, Rother MB, et al. Pre-B cell receptor signaling induces immunoglobulin k locus accessibility by functional redistribution of enhancer-mediated chromatin interactions. PLoS Biol. 2014;12(2):e1001791.
39. Kim S-I, Bultman SJ, Kiefer CM, Dean A, Bresnick EH. BRG1 requirement for long-range interaction of a locus control region with a downstream promoter. Proc Natl Acad Sci USA. 2009;106(7):2259-2264.
40. Splinter E, Heath H, Kooren J, et al. CTCF mediates long-range chromatin looping and local histone modification in the beta-globin locus. Genes Dev. 2006;20(17):2349-2354.
41. Ribeiro de Almeida C, Stadhouders R, Thongjuea S, Soler E, Hendriks RW. DNA-binding factor CTCF and long-range gene interactions in V(D)J recombination and oncogene activation. Blood. 2012;119(26):6209-6218.
42. Ong C-T, Corces VG. CTCF: an architectural protein bridging genome topology and function. Nat Rev Genet. 2014;15(4):234-246.
43. Kagey MH, Newman JJ, Bilodeau S, et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature. 2010;467(7314):430-435.
44. Zuin J, Dixon JR, van der Reijden MIJA, et al. Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells. Proc Natl Acad Sci USA. 2014;111(3):996-1001.
45. Quinodoz S, Guttman M. Long noncoding RNAs: an emerging link between gene regulation and nuclear organization. Trends Cell Biol. 2014;24(11):651-663.
46. Ørom UA, Shiekhattar R. Long noncoding RNAs usher in a new era in the biology of enhancers. Cell. 2013;154(6):1190-1193.
47. Dixon JR, Selvaraj S, Yue F, et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature. 2012;485(7398):376-380.
48. Nora EP, Lajoie BR, Schulz EG, et al. Spatial partitioning of the regulatory landscape of the X-inactivation centre. Nature. 2012;485(7398):381-385.
49. Jin F, Li Y, Dixon JR, et al. A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature. 2013;503(7475):290-294.
50. Soler E, Grosveld F. Transcription regulation in stem cells. In Durand C, Charbord P, eds. Stem Cell Biology and Regenerative Medicine. Aalborg, Denmark: River Publishers; 2014:29-58.
51. de Wit E, Bouwman BA, Zhu Y, et al. The pluripotent genome in three dimensions is shaped around pluripotency factors. Nature. 2013;501(7466):227-231.
52. Schoenfelder S, Sexton T, Chakalova L, et al. Preferential associations between co-regulated genes reveal a transcriptional interactome in erythroid cells. Nat Genet. 2010;42(1):53-61.
53. Ghamari A, van de Corput MPC, Thongjuea S, et al. In vivo live imaging of RNA polymerase II transcription factories in primary cells. Genes Dev. 2013;27(7):767-777.
54. Papantonis A, Cook PR. Transcription factories: genome organization and gene regulation. Chem Rev. 2013;113(11):8683-8705.
55. Cisse II, Izeddin I, Causse SZ, et al. Real-time dynamics of RNA polymerase II clustering in live human cells. Science. 2013;341(6146):664-667.
56. Northcott PA, Lee C, Zichner T, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014;511(7510):428-434.
57. Kovalchuk AL, Ansarah-Sobrinho C, Hakim O, et al. Mouse model of endemic Burkitt translocations reveals the long-range boundaries of Ig-mediated oncogene deregulation. Proc Natl Acad Sci USA. 2012;109(27):10972-10977.
58. Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25(4):415-427.
59. Gaj T, Gersbach CA, Barbas CF III. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7):397-405.
60. Gupta RM, Musunuru K. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest. 2014;124(10):4154-4161.
61. Kieffer-Kwon K-R, Tang Z, Mathe E, et al. Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. Cell. 2013;155(7):1507-1520.
62. Koehler AN. A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol. 2010;14(3):331-340.
63. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-4336.
64. Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood. 2012;120(15):2945-2953.
65. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839-1842.
66. Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature. 2009;460(7259):1093-1097.
67. Chen Z, Luo HY, Steinberg MH, Chui DHK. BCL11A represses HBG transcription in K562 cells. Blood Cells Mol Dis. 2009;42(2):144-149.
68. Kuo T-Y, Hsueh Y-P. Expression of zinc finger transcription factor Bcl11A/Evi9/CTIP1 in rat brain. J Neurosci Res. 2007;85(8):1628-1636.
69. Satterwhite E, Sonoki T, Willis TG, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood. 2001;98(12):3413-3420.
70. Mendenhall EM, Williamson KE, Reyon D, et al. Locus-specific editing of histone modifications at endogenous enhancers. Nat Biotechnol. 2013;31(12):1133-1136.
71. Mukhopadhyay M, Teufel A, Yamashita T, et al. Functional ablation of the mouse Ldb1 gene results in severe patterning defects during gastrulation. Development. 2003;130(3):495-505.
72. Love PE, Warzecha C, Li L. Ldb1 complexes: the new master regulators of erythroid gene transcription. Trends Genet. 2014;30(1):1-9.
73. Deng W, Lee J, Wang H, et al. Controlling long-range genomic interactions at a native locus by targeted tethering of a looping factor. Cell. 2012;149(6):1233-1244.
74. Deng W, Rupon JW, Krivega I, et al. Reactivation of developmentally silenced globin genes by forced chromatin looping. Cell. 2014;158(4):849-860.
75. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358(13):1362-1369.
76. Fu Y, Foden JA, Khayter C, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822-826.
77. Cho SW, Kim S, Kim Y, et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 2014;24(1):132-141.
78. Komáromy AM, Alexander JJ, Rowlan JS, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010;19(13):2581-2593.
79. Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32(6):551-553.
80. Mandal PK, Ferreira LMR, Collins R, et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell. 2014;15(5):643-652.